Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

A single interactive map for all that is known on COVID-19


Dr. Anna Niarakis, teaching researcher in bioinformatics and computational systems biology at the Genopole laboratory GenHotel (University of Évry) is one of the four coordinators for the international COVID-19 Disease Map project.
COVID-19 Disease Map >
Covid-19 D Covid-19 D

Responding to a call made by the Disease Maps community, close to 200 scientists from 100 institutions in 24 countries are participating in the project.
The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

This major collaborative project has resulted in a platform that is available to the entire scientific community and constantly evolving as knowledge on COVID-19 advances. Presented in the form of an interactive map, the platform compiles all available data on virus/human-host molecular interactions and their roles in the complex mechanisms of the disease: infection processes, biological pathways and affected cells, viral proliferation, inflammatory responses, etc. In this way, the contributors to the project hope to more effectively increase our understanding of COVID-19 and accelerate the development of diagnostics and therapeutics.

As the project’s modeling coordinator, Anna Niarakis will deploy the dynamic modeling tool she developed at Inria within the GenHotel laboratory originally for rheumatoid arthritis. That tool enables virtual testing of the effects of perturbations on disease course, particularly viral proliferation, cellular death and inflammation. By crossing such analyses with therapeutics databases, it becomes possible to identify drug candidates.

Logo - Covid-19 Disease Map

COVID-19 Disease Map

The COVID-19 Disease Map enables visual explorations and computational analyses of the molecular mechanisms involved in SARS-CoV-2 viral entry and multiplication, virus/host interactions, immune responses and cell recuperation. The main challenge it faces is to associate rapidity and reliability in the race against the unprecedented COVID-19 pandemic. This includes not only the exhaustive collection of data, but also the verification of the reliability of those data, which are often taken from increasingly present preprint articles. Bioinformaticians organize and explore those highly informative data then biologists, virologists and clinicians verify models.

COVID-19 Disease Map: providing all competencies

The active participation of close to 200 scientists provides all the competencies needed for a better understanding of COVID-19:

  • the molecular and clinical aspects of the pathology;
  • molecular interaction characterizations and systems biology schemas illustrating disease mechanisms;
  • medical literature reviews;
  • the integration of diverse databases and bioinformatics expertise;
  • computational modeling to analyze disease-associated perturbations via systems biology approaches.

The initiative: mutualize expertise and energy to meet the challenges of COVID-19

The COVID-19 Disease Map project is an interdisciplinary effort involving researchers and clinicians with complementary competencies to rise to the challenge of COVID-19. It benefits from the participation of renowned international scientific groups that strengthen the project in a wide range of domains. The various project orientations progress together thanks to the volunteer work and enthusiasm of the project’s community.

The international scientific community’s massive participation in the project stands as a positive signal for the future, wherein all can indeed come together for a shared cause, achieve concrete results and accelerate the fight against a sinister disease.

The GenHotel lab actively engaged in the battle

Four people are in charge of managing and advancing the COVID-19 Disease Map project: Dr. Marek Ostaszewski (University of Luxembourg), Dr. Alexander Mazein (University of Luxembourg), Dr. Inna Kuperstein (Institut Curie) and Dr. Anna Niarakis (University of Évry, Paris-Saclay University).

Dr. Anna Niarakis is an associate professor at the University of Évry–Paris-Saclay and a researcher at GenHotel, the Genopole laboratory for complex diseases and rheumatoid arthritis. From day one of the project, she has been actively involved in several axes:

  • project conception and management;
  • map construction;
  • development of data analysis pipelines and dynamic modeling.

She has teamed with Vidisha Singh, PhD student at GenHotel and Sara Sadat Aghamiri, Inserm engineer at the Saint-Louis Hospital and GenHotel to construct graphs of disease-associated biological mechanisms using SBGN (Systems Biology Graphical Notation Scheme) notation and MIRIAM (Minimum Information Required in the Annotation) identifiers.
Their team deploys competencies to construct large-scale molecular maps, including the recently-published rheumatoid arthritis map. (show map).

Dr. Niarakis also coordinates bioinformatics analysis and computational modelling for the COVID-19 Disease Map project. A program called CasQ, which she developed with Sylvain Soliman of INRIA-Saclay’s Lifeware team and recently published in Bioinformatics (read the article), is used in that setting to produce discrete models executable at a large scale from molecular maps.

The COVID-19 Disease Map objectives in brief:

The COVID-19 molecular map will:

  1. serve as a high-quality, complete, easily-accessed resource with human curation;
  2. provide integrated solutions for textual exploration and artificial-intelligence assisted data exploration for improved content conservation and enrichment;
  3. ensure free access to reusable and interoperable content that interfaces with other databases and data referentials;
  4. provide a multi-omic data analysis platform with assisting disease maps, drug repurposing information and clinical data integration systems;
  5. furnish a mechanistic model for the development of computer models for in silico simulations of combined perturbations (KO, KI) and predictions of novel therapeutic targets;
  6. act as a community hub enabling the development of state of the art technologies for tomorrow’s medical challenges.

To learn more about the COVID-19 Disease Map project

Click here if you would like to contribute to the project

Article posted on 5 May 2020

Share
Highlights

The latest news


Journée Croda - table ronde intitulée « Essais cliniques phases 1 et 2 : comment surmonter les obstacles réglementaires et financiers ? » Nov. 2024

Genopole and Croda Pharma ally for the Biopharma Innovation Summit

Genopole partnered with Croda Pharma to organize the Biopharma Innovation Summit, a day-long scientific event dedicated to biopharmaceutical innovation.

Discover
Ibisc - Genopole's Laboratory

Optimizing the vital debriefing step in virtual reality training

The IBISC laboratory has developed an immersive debriefing module for virtual reality training and demonstrated its ability to optimize the vital debriefing step in that setting.

Discover
Genopole Partnering Week 2024 - un format hybride au service des biotechs

Partnering Week 2024: a hybrid edition for biotech innovation

Discover the highlights of Genopole Partnering Week 2024 (#GPW2024): a hybrid event bringing together start-ups, investors, and industry leaders to accelerate biotech innovation in health and the environment.

Discover
L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
View all >
With the support from
Région île de France